MDxHealth SA (FRA:O6C1)

Q2 2026 MDxHealth SA Earnings Call Transcript

Aug 13, 2026 / 08:30 PM GMT

Release Date Price: €0.108 (+30.91%)

Transcript

Key Points

Positve

MDxHealth SA (MDXH) delivered a 14% sequential revenue increase in Q2 2026, the largest quarter-over-quarter acceleration in company history.
The company successfully transitioned all Resolve customers by the end of Q2, maintaining customer relationships and building credibility.
MDxHealth SA (MDXH) eliminated a $10.4 million contingent liability to Novitas by winding down its Plano, Texas lab operations.
The company strengthened its balance sheet with a $20 million registered direct financing at market price with no discount or warrants.
Management reaffirmed full-year 2026 revenue guidance of $110 million to $115 million and expects to return to positive adjusted EBITDA by year-end.

Negative

Gross margins decreased by 2.9 percentage points year-over-year to 65.7%, primarily due to a shift in product mix toward liquid-based tests.
Operating loss widened to $5.1 million in Q2 2026, compared to a $1.5 million loss in the prior year period, driven by ExoDx acquisition costs.
Net loss increased 36% year-over-year to $9.5 million, reflecting higher operating expenses from the ExoDx acquisition.
Adjusted EBITDA turned negative at -$2.3 million in Q2 2026, versus a positive $1.1 million in Q2 2025.
Tissue-based test volumes remained flat year-over-year, with management acknowledging the need to return to prior growth rates to meet guidance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDXH.OQ - MDxHealth SA
Q2 2026 MDxHealth SA Earnings Call
Aug 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome everyone joining today's MDX Health Second Quarter 2026 Earnings Conference Call.

At this time, all participants are in a listen-only mode.

Later, you will have the opportunity to ask questions during the question-and-answer session.

To register to ask a question at any time, please press star one on your telephone keypad.

Please note this call is being recorded and we are standing by if you should need any assistance.

It is now my pleasure to turn the meeting over to John Francis with LifeSci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.